Trial Profile
Phase II Trial of M7824 in Subjects With HPV Associated Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Bintrafusp alfa (Primary)
- Indications Anal cancer; Cervical cancer; Head and neck cancer; Neuroendocrine carcinoma; Oropharyngeal cancer; Penile cancer; Rectal cancer; Solid tumours; Squamous cell cancer; Vulvovaginal cancer
- Focus Therapeutic Use
- 01 Mar 2023 Status changed from active, no longer recruiting to completed.
- 23 Nov 2021 Planned End Date changed from 31 Dec 2023 to 31 Dec 2022.
- 12 Sep 2021 According to a EMD Serono media release, data from this trial will be presented at ESMO 2021 on Thursday, September 16.